Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2010

Conditions
Pre-hypertension
Interventions
DRUG

carvedilol phosphate

Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months

DRUG

lisinopril

tablets, 10mg once daily for 1 month, 20mg once daily for 8 months

DRUG

carvedilol phosphate and lisinopril

carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months

DRUG

placebo and placebo

capsule once daily for 9 months; dosage unknown

Trial Locations (1)

55455

University of Minnesota, Variety Club Research Center 102, Minneapolis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Minnesota

OTHER

NCT00553969 - Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease | Biotech Hunter | Biotech Hunter